Corporate | 1 March 2006 10:00
Planegg-Martinsried, Germany, 01 March 2006
– 4SC AG (Frankfurt, Prime Standard: VSC), a German drug discovery and development company announced today that the company will be presenting at Biosquare 2006 in Geneva, Switzerland. The conference is being held at the International Conference Center.
The presentation will be given by Dr Ulrich Dauer, Chief Executive Officer of 4SC AG on Thursday, March 9, 2006 at 12.45 p.m. local time. Dr Dauer will give a review of the company and update the audience on current clinical and business developments.
About 4SC:
4SC (ISIN DE0005753818) develops novel drug candidates for inflammatory diseases and cancer using a cheminformatics based technology platform. Traditional high throughput screening of therapeutic agents has been transferred from the lab to the computer. Thus, the company offers substantial cost and time advantages as well as increased success rates in drug development. 4SC uses its patented technology platform to create a sustainable product pipeline for active agents that are developed in early clinical phases (‘proof of concept’) and subsequently result in upfront and milestone payments as well as participation in sales generated by out-licensed products to the pharmaceutical industry. The pipeline currently has five projects, the first of which, on the treatment of rheumatoid arthritis, has successfully completed clinical phase I. Preparations for the conduct of the IIa clinical phase are well under way. A further one to two other product candidates should go into clinical development in 2006. Furthermore, the company has its technology platform in co-operation projects with biotech and pharma companies and is already generating initial revenues.
This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.